Virus-induced Cell Fate Decisions in Anti-Viral Immunity

抗病毒免疫中病毒诱导的细胞命运决定

基本信息

  • 批准号:
    8653359
  • 负责人:
  • 金额:
    $ 210万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2019-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (as provided by applicant): The lack of effective vaccines and therapeutic treatments for many viruses presents a significant health concern. Host defenses against viruses require adaptive immune functions provided by both B cells and T cells, but the cellular and molecular processes that control the functions and cell fate decisions of these cells are incompletely understood. Although the persistence of viral antigens, the cytokine milieu in local microenvironments, the concentration and placement of immune cells in lymphoid and non-lymphoid organs, and the availability and type of co-stimulation can all dramatically affect the ultimate biological outcome of an immune response to virus infection or vaccination, it is unclear how these factors are controlled or how viruses manipulate each of these factors to evade or subvert immunity. These basic knowledge gaps limit our ability to rationally design new vaccines and develop interventions to treat virus-mediated diseases. Therefore the overall goal of this U19 Program is to determine how various types of virus infections (chronic-systemic, acute-systemic, and acute-mucosal) affect the factors described above and lead to specific types of immune responses that may be beneficial or pathologic. In order to meet this goal, five labs with complementary expertise in human and mouse antiviral immunology will work collaboratively to address some of these key unresolved issues in antiviral immunity. In Project 1, Troy Randall at UAB will determine how Tfh responses are controlled by IL-2 signaling and availability. In Project 2, Allan Zajac at UAB will determine how antiviral CD8+ T cells responses are controlled by adhesion molecules and T cell clustering. In Project 3, Frances Lund at UAB will determine how antiviral B cell responses are controlled by IFN? signaling and availability. In Project 4, Nicole Baumgarth of UC Davis will determine how natural and induced antiviral IgM responses are controlled. These projects will be facilitated by Core A - Administration and Biostatistics (Troy Randall), Core B - Viral Stocks and Reagents (Frances Lund), and Core C - Human Immunology (Frances Eun-Hyung Lee, Emory). Importantly, all projects will be able to examine virus-specific B and T cells using tetramer reagents developed by Core B. In addition, although many of the mechanistic studies in each project will be performed using mouse models, the projects will also test key hypotheses in humans via interactions with the Human Immunology Core (Core C).
描述(如申请人所提供):缺乏针对许多病毒的有效疫苗和治疗方法是一个重大的健康问题。宿主对病毒的防御需要由B细胞和T细胞提供的适应性免疫功能,但是控制这些细胞的功能和细胞命运决定的细胞和分子过程还不完全清楚。尽管病毒抗原的持久性、局部微环境中的细胞因子环境、淋巴和非淋巴器官中免疫细胞的浓度和位置以及共刺激的可用性和类型都可以显著影响对病毒感染或疫苗接种的免疫应答的最终生物学结果,目前还不清楚这些因素是如何控制的,也不清楚病毒是如何操纵这些因素中的每一个来逃避或破坏免疫力的。这些基本知识差距限制了我们合理设计新疫苗和开发治疗病毒介导疾病的干预措施的能力。因此,U19计划的总体目标是确定各种类型的病毒感染(慢性全身性、急性全身性和急性粘膜性)如何影响上述因素,并导致可能有益或病理性的特定类型的免疫应答。为了实现这一目标,在人类和小鼠抗病毒免疫学方面具有互补专业知识的五个实验室将合作解决抗病毒免疫中一些关键的未解决问题。在项目1中,UAB的Troy Randall将确定Tfh反应如何受IL-2信号传导和可用性控制。在项目2中,UAB的Allan Zajac将确定抗病毒CD 8 + T细胞反应如何由粘附分子和T细胞聚集控制。在项目3中,UAB的Frances隆德将确定IFN如何控制抗病毒B细胞反应?信令和可用性。在项目4中,加州大学戴维斯分校的Nicole Baumgarth将确定如何控制自然和诱导的抗病毒IgM反应。这些项目将由核心A -管理和生物统计学(Troy Randall)、核心B -病毒储备和试剂(Frances隆德)和核心C -人类免疫学(Frances Eun-Hyung Lee,Emory)促进。重要的是,所有项目将能够使用Core B开发的四聚体试剂检查病毒特异性B和T细胞。此外,虽然每个项目中的许多机制研究将使用小鼠模型进行,但这些项目还将通过与人类免疫学核心(Core C)的相互作用来测试人类的关键假设。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Troy D Randall其他文献

Troy D Randall的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Troy D Randall', 18)}}的其他基金

Multi-parameter, analytic flow cytometer
多参数分析流式细胞仪
  • 批准号:
    10426996
  • 财政年份:
    2022
  • 资助金额:
    $ 210万
  • 项目类别:
Protective functions of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的保护功能
  • 批准号:
    10194374
  • 财政年份:
    2020
  • 资助金额:
    $ 210万
  • 项目类别:
Protective functions of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的保护功能
  • 批准号:
    10410377
  • 财政年份:
    2020
  • 资助金额:
    $ 210万
  • 项目类别:
Molecular Analysis and Lineage Tracing of Influenza-Specific, Lung-Resident Memory B Cells
流感特异性肺驻留记忆 B 细胞的分子分析和谱系追踪
  • 批准号:
    10373018
  • 财政年份:
    2020
  • 资助金额:
    $ 210万
  • 项目类别:
Protective functions of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的保护功能
  • 批准号:
    10033774
  • 财政年份:
    2020
  • 资助金额:
    $ 210万
  • 项目类别:
B cell Receptor repertoire, cloning and expression Core
B 细胞受体库、克隆和表达核心
  • 批准号:
    10395998
  • 财政年份:
    2019
  • 资助金额:
    $ 210万
  • 项目类别:
B cell Receptor repertoire, cloning and expression Core
B 细胞受体库、克隆和表达核心
  • 批准号:
    10592411
  • 财政年份:
    2019
  • 资助金额:
    $ 210万
  • 项目类别:
Role of microbiota in therapy to ovarian cancer
微生物群在卵巢癌治疗中的作用
  • 批准号:
    9898344
  • 财政年份:
    2017
  • 资助金额:
    $ 210万
  • 项目类别:
Role of microbiota in therapy to ovarian cancer
微生物群在卵巢癌治疗中的作用
  • 批准号:
    9307067
  • 财政年份:
    2017
  • 资助金额:
    $ 210万
  • 项目类别:
Role of microbiota in therapy to ovarian cancer
微生物群在卵巢癌治疗中的作用
  • 批准号:
    10115635
  • 财政年份:
    2017
  • 资助金额:
    $ 210万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 210万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了